يعرض 1 - 20 نتائج من 30 نتيجة بحث عن '"Usona Institute"', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1
    Report

    المصدر: A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression

  2. 2
    Report

    المؤلفون: Usona Institute

    المصدر: Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

  3. 3
    Report

    المؤلفون: Usona Institute

    المصدر: An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
    Gunderson J: Borderline Personality Disorder, 2nd ed. Washington, DC, American Psychiatric Press, 2000
    Nakao K, Gunderson JG, Phillips KA, Tanaka N: Functional impairment in personality disorders. J Pers Disord 1992; 6:24-31
    Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006 Jul;63(7):757-66. doi: 10.1001/archpsyc.63.7.757. Erratum In: Arch Gen Psychiatry. 2007 Dec;64(12):1401.
    Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008 Apr;165(4):468-78. doi: 10.1176/appi.ajp.2007.07071079. Epub 2008 Feb 15. Erratum In: Am J Psychiatry. 2008 Jun;165(6):777.
    McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry. 2012 Jun;169(6):650-61. doi: 10.1176/appi.ajp.2012.11091416.
    Lieb K, Vollm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010 Jan;196(1):4-12. doi: 10.1192/bjp.bp.108.062984.
    Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833-8. doi: 10.1176/ajp.2006.163.5.833.
    Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008 Dec;193(6):485-92. doi: 10.1192/bjp.bp.107.037903.
    Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353-62. doi: 10.4088/JCP.08m04138yel.
    Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, Perez V. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603-8. doi: 10.4088/jcp.v69n0412.
    Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003 Jun;17(3):233-42. doi: 10.1521/pedi.17.3.233.22147. Erratum In: J Personal Disord. 2003 Aug;17(4):1 p following 369.

  4. 4
    Report

    المساهمون: Charles Raison, Vail Health Behavioral Health Innovation Center Director

    المصدر: An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

  5. 5
    Report

    المؤلفون: Usona Institute

    المساهمون: Benjamin Kelmendi, MD, Assistant Professor

    المصدر: Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals with Functional Impairment Related to Mood, Anxiety, Trauma And/or Addiction Symptoms: an Open-label Proof-of-concept Study

  6. 6
    Report

    المؤلفون: Usona Institute

    المصدر: Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

  7. 7
    Report

    المساهمون: Benjamin Lewis, Assistant Professor of Psychiatry

    المصدر: PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout

  8. 8
    Report

    المصدر: Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase

  9. 9
    Report
  10. 10
    Report

    المؤلفون: Usona Institute

    المصدر: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

  11. 11
    Report

    المصدر: The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study

  12. 12
    Report

    المساهمون: Joshua Woolley, Assistant Professor

    المصدر: Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
    Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Sep 24;27:100538. doi: 10.1016/j.eclinm.2020.100538. eCollection 2020 Oct.

  13. 13
    Academic Journal

    المساهمون: National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, National Science Foundation, Brain and Behavior Research Foundation, Simons Foundation Autism Research Initiative, Heffter Research Institute, Swiss Neuromatrix Foundation, Swiss National Science Foundation under the framework of Neuron Cofund, Usona Institute

    المصدر: eLife ; volume 13 ; ISSN 2050-084X

  14. 14
    Academic Journal

    المساهمون: Usona Institute

    المصدر: Pharmacology Research & Perspectives ; volume 12, issue 4 ; ISSN 2052-1707 2052-1707

  15. 15
    Academic Journal

    المساهمون: Mary Sue and Mike Shannon Distinguished Chair for Healthy Minds, Children and Families, Usona Institute

    المصدر: Religion, Brain & Behavior ; page 1-17 ; ISSN 2153-599X 2153-5981

  16. 16
    Academic Journal

    المساهمون: National Institute on Drug Abuse, Usona Institute

    المصدر: ACS Chemical Neuroscience ; volume 15, issue 2, page 315-327 ; ISSN 1948-7193 1948-7193

  17. 17
    Academic Journal

    المساهمون: Center for Psychedelic and Consciousness Research, Tim Ferriss, Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, and the Steven and Alexandra Cohen Foundation, Center for Psychedelic Drug Research and Education, Usona Institute

    المصدر: Journal of Psychoactive Drugs ; page 1-11 ; ISSN 0279-1072 2159-9777

  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20
    Academic Journal